Medtronic receives ce mark for its next generation micra leadless pacing systems

New pacemakers offer 40% more battery life,1 extend medtronic legacy of pacing leadership dublin , jan. 5, 2024 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced it has received ce (conformitÉ europÉenne) mark for its micra™ av2 and micra™ vr2, the next generation of its industry-leading miniature, leadless pacemakers. micra av2 and micra vr2, the world's smallest pacemakers, provide longer battery life and easier programming than prior micra pacemakers, while still delivering the many benefits of leadless pacing such as reduced complications compared to traditional pacemakers.2 with approximately 40% more battery life compared to previous generations,1 medtronic projects the battery life of micra av2 and micra vr2 is nearly 16 and 17 years, respectively.3 this means more than 80% of patients who receive a micra may only require one device for life.3 this ce mark milestone follows u.s. food and drug administration approval for the micra av2 and vr2 devices in 2023.
MDT Ratings Summary
MDT Quant Ranking